Skip to main content
AbbVie Inc. logo

AbbVie Inc. - Investor Relations & Filings

Listed IPO Jan 2013
Ticker · ABBV ISIN · US00287Y1091 LEI · FR5LCKFTG8054YNNRU85 US Manufacturing
Open in API
Filings indexed 1,588 across all filing types
Latest filing 2026-07-06 Earnings Release
Country US United States of America
Listing US ABBV · 18 venues

Key figures FY2025

Period ended 2025-12-31 · USD
Headline annual figures for AbbVie Inc., fiscal year 2025, reported in USD, with the source filing for each figure.
Total Assets USD 15.95B per the Annual Report filed 2026-06-24
Total Equity USD 15.95B per the Annual Report filed 2026-06-24

As reported by the issuer in the filings linked above. Figures are normalized for comparability; consult the source filing for the authoritative statement.

About AbbVie Inc.

https://www.abbvie.com/

AbbVie Inc. is a global, research-based biopharmaceutical company focused on the discovery, development, manufacturing, and commercialization of innovative medicines and therapeutic solutions. The company's mission is to address complex health issues and make a significant impact on patients' lives by combining advanced science with deep expertise. AbbVie develops treatments across various therapeutic areas, aiming to solve serious health challenges. In addition to its proprietary product pipeline, the company also offers contract manufacturing services for both small molecules and biologics, supporting other pharmaceutical partners in their development and production needs.

Recent filings

Filing Released Lang Actions
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC. Item 2.02 specifically addresses 'Results of Operations and Financial Condition', providing preliminary earnings guidance and financial updates for the second quarter of 2026. According to the filing definitions, documents that announce quarterly financial results, including preliminary or unaudited results, are classified as Earnings Releases (ER). While it is an 8-K, the content is fundamentally an earnings-related update. Q2 2026
2026-07-06 English
11-K
Annual Report Classification · 95% confidence The document is a Form 11-K filing with the SEC, which is an annual report for employee stock purchase, savings, and similar plans. It covers the fiscal year ended December 31, 2025, and includes detailed financial statements, auditor's opinion, notes to the financial statements, and supplemental schedules related to the AbbVie Savings Plan. The content is comprehensive and consists of audited financial data, meeting the criteria for an official annual report for such employee benefit plans. This matches the description of an Annual Report type of filing (10-K style for employee benefit plans). Thus, the filing is correctly classified as 10-K (Annual Report). FY 2025
2026-06-24 English
M&A announcement
Call Transcript Classification · 100% confidence
2026-06-22 English
FORM 8-K
M&A Activity Classification · 100% confidence The document is a Form 8-K Current Report filed with the SEC by AbbVie Inc., dated June 18, 2026. It reports a definitive agreement to acquire Apogee Therapeutics, including a press release and an investor presentation as exhibits. The document is principally an announcement of a corporate transaction (an acquisition) and related disclosures, typical of merger and acquisition activity. It is not a financial report such as an Annual Report (10-K) or Quarterly Report (IR), nor is it a call transcript or governance document. It is not merely an announcement of a report publication but a substantive filing related to M&A. Given the description and content, the appropriate classification is M&A Activity (TAR). The document length (ca. 12,000+) supports that this is not just a short notice but a formal M&A-related filing.
2026-06-22 English
Goldman Sachs 47th Annual Global Healthcare Conference 2026
Call Transcript Classification · 100% confidence
2026-06-09 English
FORM SD
Regulatory Filings Classification · 94% confidence The document is a Form SD (“Specialized Disclosure Report”) filed with the SEC under Rule 13p-1 to disclose conflict minerals information. It is not an annual or quarterly report, proxy, earnings release, management discussion, or other specific category listed. It is a standard regulatory filing for specialized disclosure. Therefore it falls under the fallback “Regulatory Filings” category (RNS).
2026-06-01 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.